Standard anticoagulation

PreclinicalSmall molecule

Standard anticoagulation is one of 40 small molecule programs targeting Pulmonary Embolism. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary EmbolismActive, not recruiting

Pulmonary EmbolismPreclinical

Active, not recruiting

Competition

Competitive Landscape

81 competitors in Pulmonary Embolism

#DrugCompanyPhaseTrials

Innohep

Alnylam Pharmaceuticals

Approved

1 2

Savaysa

Daiichi Sankyo

Approved

—3

Unfractionated Heparin

GSK

Approved

3 4

Activase

Roche

Phase 3

7 5

Tnkase

Roche

Phase 3

2 6

Actilyse

Boehringer Ingelheim

Approved

1 7

Heparin Sodium

BBaxter Healthcare Corporation

Phase 3

2 8

Low-Molecular-Weight Heparin

Daiichi Sankyo

Phase 3

4 9

Acenocoumarol

Roche

Approved

1 10

Lovenox

Sanofi

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ARecruiting

Pulmonary Embolism

NCT06487052

Q1 2028

Post-ApprovalRecruiting

Pulmonary Embolism

NCT05493163

Clinical

Trials by Indication[1]

Pulmonary Embolism2 trials

Catheter-directed Thrombolysis in Intermediate-high Risk Acute Pulmonary Embolism

Recruiting·FFaculty Hospital Kralovske Vinohrady·Phase 4·NCT05493163·558 enrolled

Evaluation of the Standard Catheter-directed Thrombolysis Effectiveness in Intermediate-High-Risk Pulmonary Embolism Patients

Recruiting·FFederal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health·N/A·NCT06487052·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Standard anticoagulation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Standard anticoagulation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Standard anticoagulation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Faculty Hospital Kralovske Vinohrady company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFaculty Hospital Kralovske Vinohrady

Standard anticoagulation

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2028

Trials by Indication[1]

Pulmonary Embolism2 trials

References

Drug Info

Quick Facts

Related News